Abbott receives FDA authorization for Libre Duo with glucose and ketone monitoring
Abbott has introduced Libre Duo, the first 2-in-1 continuous glucose monitor authorized by the U.S. Food and Drug Administration (FDA). The device is intended for people with diabetes and allows them to track glucose and ketone levels. A prescription is required to use it.
Monitoring two indicators
According to The Verge, the Libre Duo sensor is designed for 10 days of use. Its operating principle is similar to Abbott's other continuous glucose monitors, but it also measures ketone levels.
The new device is intended to help people with diabetes monitor ketone levels alongside glucose readings. The combination of these two functions is its main feature.
More current news is available on the UA.News Telegram channel Telegram.
Risk of ketoacidosis
In an article by The Verge, author Victoria Song described her own experience with ketoacidosis as a teenager. According to her, after following a low-carbohydrate diet without medical supervision, the ketone level in her blood reached a toxic level, which required emergency medical care.
Libre Duo combines continuous glucose tracking with ketone monitoring in one sensor. The device is prescription-only and designed to be worn for 10 days.
